share_log

Wedbush Reiterates Outperform on Beam Therapeutics, Maintains $57 Price Target

Wedbush Reiterates Outperform on Beam Therapeutics, Maintains $57 Price Target

Wedbush重申Beam Therapeutics的跑赢大盘,维持57美元的目标股价
Moomoo 24/7 ·  04/23 12:32

Wedbush analyst David Nierengarten reiterates Beam Therapeutics (NASDAQ:BEAM) with a Outperform and maintains $57 price target.

Wedbush分析师戴维·尼伦加滕重申Beam Therapeutics(纳斯达克股票代码:BEAM)的表现跑赢大盘,并维持57美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发